Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker AUTL
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Qatar Investment Authority | 9.18M | 3.5% | SCHEDULE 13G/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Stephen A. Schwarzman | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Blackstone Group Management L.L.C. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Blackstone Inc. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Blackstone Holdings I/II GP L.L.C. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Blackstone Holdings II L.P. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | BXLS V L.L.C. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Blackstone Life Sciences Associates V (CYM) L.L.C. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | BXLS V - Autobahn L.P. | 20.49M | 7.6% | SCHEDULE 13D/A ↗ |
| Aug 28, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | PPF IM Ltd. | 14.78M | 5.6% | SCHEDULE 13D/A ↗ |
| Aug 28, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | PPF Group a.s. | 14.78M | 5.6% | SCHEDULE 13D/A ↗ |
| Aug 28, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | AMALAR HOLDING s.r.o. | 14.78M | 5.6% | SCHEDULE 13D/A ↗ |
| Aug 28, 2026 | SCHEDULE 13D/A (amended) | AUTL Autolus Therapeutics plc | Renata Kellnerova | 14.78M | 5.6% | SCHEDULE 13D/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Steven Boyd | 15.00M | 5.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Armistice Capital, LLC | 15.00M | 5.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Michael A. Kaufman | 33.62M | 12.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Mak Capital One LLC | 33.62M | 12.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | MAK Capital Fund LP | 33.62M | 12.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Steven Boyd | 15.80M | 5.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Armistice Capital, LLC | 15.80M | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Steven Boyd | 17.50M | 6.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Armistice Capital, LLC | 17.50M | 6.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Michael A. Kaufman | 30.01M | 11.3% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | MAK Capital One L.L.C. | 30.01M | 11.3% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | MAK Capital Fund LP | 30.01M | 11.3% | SCHEDULE 13G/A ↗ |
| Dec 3, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Michael A. Kaufman | 26.89M | 10.1% | SCHEDULE 13G/A ↗ |
| Dec 3, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | MAK Capital One L.L.C. | 26.89M | 10.1% | SCHEDULE 13G/A ↗ |
| Dec 3, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | MAK Capital Fund LP | 26.89M | 10.1% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G | AUTL Autolus Therapeutics plc | Steven Boyd | 15.60M | 5.9% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G | AUTL Autolus Therapeutics plc | Armistice Capital, LLC | 15.60M | 5.9% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | David Kroin | 2.57M | 1.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Deep Track Biotechnology Master Fund, Ltd. | 2.57M | 1.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Deep Track Capital, LP | 2.57M | 1.0% | SCHEDULE 13G/A ↗ |
| Oct 6, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Wellington Investment Advisors Holdings LLP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 6, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Wellington Group Holdings LLP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 6, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Wellington Management Group LLP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Jun 25, 2025 | SCHEDULE 13G | AUTL Autolus Therapeutics plc | Michael A. Kaufman | 15.41M | 5.8% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | AUTL Autolus Therapeutics plc | MAK Capital One L.L.C. | 15.41M | 5.8% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | AUTL Autolus Therapeutics plc | MAK Capital Fund LP | 15.41M | 5.8% | SCHEDULE 13G ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Abigail P. Johnson | 10.16M | 3.8% | SCHEDULE 13G/A ↗ |
| May 12, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | FMR LLC | 10.16M | 3.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Kenneth Galbraith | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Christopher Hollowood | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Roel Bulthuis | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Syncona Limited | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Syncona Investment Management Limited | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Syncona Holdings Limited | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| May 7, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Syncona Portfolio Limited | 28.82M | 10.8% | SCHEDULE 13G/A ↗ |
| Apr 4, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Wellington Management Company LLP | 27.09M | 10.1% | SCHEDULE 13G/A ↗ |
| Apr 4, 2025 | SCHEDULE 13G/A (amended) | AUTL Autolus Therapeutics plc | Wellington Investment Advisors Holdings LLP | 27.09M | 10.2% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances